Bioequivalence of Entacapone, Levodopa and Carbidopa Tablets (II) in Healthy Subjects

Phase 1, randomised, open-label trial of carbidopa/levodopa/entacapone in Parkinson's disease (PD) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration at 10 hours, Area under the plasma concentration versus time curve from time zero to the last measurable concentration at 10 hours and 1 more. Status: unknown.